17-(1′propenyl)-17-3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative
The invention relates to 17-(1′-propenyl)-17-3′-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the residues Z, R 4 , R 6a , R 6b , R 7 , R 15 , R 16a , R 16b and R 18 have the meanings stated in Claim 1 , and their solvates, hydrates and salts, including all stereoisomers of these compounds. The invention further relates to the use of these derivatives for the production of a medicinal product for oral contraception and for the treatment of pre-, peri- and postmenopausal complaints and medicinal products that contain said derivatives, and in particular application in the aforementioned indications. The derivatives according to the invention have a progestational and in preferred cases additionally an antimineralocorticoid and neutral to slightly androgenic action.
1. The 17-(1′-Propenyl)-17-3′-oxidoestra-4-en-3-one derivative selected from the group comprising of:
7α-Methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7β-Methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7α-Ethyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7β-Ethyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7α-Vinyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7β-Vinyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7α-Cyclopropyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7β-Cyclopropyl-17α-(1-propenyl)-17β-3′-oxidoestra-4-en-3-one;
6-Methylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
6α-Hydroxymethylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
6β-Hydroxymethylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
6,6-(1,2-Ethanediyl)-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
6α,7α-Methylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
6β,7β-Methylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
17α-(1′-Propenyl)-17β-3′-oxidoestra-4,6-dien-3-one;
16,16-(1,2-Ethanediyl)-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
(E/Z)-3-(Hydroxyimino)-7α-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7β-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7α-ethyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7β-ethyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7α-vinyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7β-vinyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7α-cyclopropyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7β-cyclopropyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6-methylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6α-hydroxymethylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6β-hydroxymethylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6,6-(1,2-ethanediyl)-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6α,7α-methylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6β,7β-methylene-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-17α-(1′-propenyl)-17β-3′-oxidoestra-4,6-diene;
(E/Z)-3-(Hydroxyimino)-16,16-(1,2-ethanediyl)-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
7 α,18-Dimethyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7 β,18-Dimethyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7β-Ethyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7α-Vinyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7β-Vinyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7α-Cyclopropyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
7β-Cyclopropyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-en-3-one;
6-Methylene-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-en-3-one;
6α-Hydroxymethylene-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-en-3-one;
6,6-(1,2-Ethanediyl)-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-en-3-one;
6α,7α-Methylene-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-en-3-one;
6β,7β-Methylene-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-en-3-one;
17α-(1′-Propenyl)-18-methyl-17β-3′-oxidoestra-4,6-dien-3-one;
16,16-(1,2-Ethanediyl)-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-en-3-one;
(E/Z)-3-(Hydroxyimino)-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7α,18-dimethyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7β,18-dimethyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7α-ethyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7β-ethyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7α-vinyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7β-vinyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7α-cyclopropyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-7β-cyclopropyl-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6-methylene-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6α-hydroxymethylene-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6β-hydroxymethylene-17α-(1-propenyl)-18-methyl-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6,6-(1,2-ethanediyl)-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6α,7α-methylene-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-6β,7β-methylene-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-ene;
(E/Z)-3-(Hydroxyimino)-18-methyl-17α-(1′-propenyl)-17β-3′-oxidoestra-4,6-diene; and
(E/Z)-3-(Hydroxyimino)-16,16-(1,2-ethanediyl)-17α-(1′-propenyl)-18-methyl-17β-3′-oxidoestra-4-ene.
2. A medicinal product, containing at least one 17-(1′-propenyl)-17-3′-oxidoestra-4-en-3-one derivative as claimed in claim 1 and at least one suitable pharmaceutically harmless additive.
3. The medicinal product as claimed in claim 2 , additionally containing at least one estrogen.
4. The medicinal product as claimed in claim 3 , characterized in that the estrogen is ethinylestradiol.
5. The medicinal product as claimed in claim 3 , characterized in that the estrogen is estradiol valerate.
6. The medicinal product as claimed in claim 3 , characterized in that the estrogen is a natural estrogen.
7. The medicinal product as claimed in claim 6 , characterized in that the natural estrogen is estradiol.
8. The medicinal product as claimed in claim 6 , characterized in that the natural estrogen is a conjugated estrogen.
9. A method of contraception comprising the step of administering a compound according to claim 1 to a woman in need thereof.